DxTerity Diagnostics and City of Hope Announce Therapeutics Collaboration
News Dec 04, 2008
NEAT™ is a versatile genomics testing platform that enables gene-controlled ligation (joining) of oligonucleotide probes inside of cells (in-situ). This specific technique will be used to develop in-situ assembled antisense therapeutics. Unlike traditional therapeutics that work by binding to proteins, antisense therapeutics work at the genomic level to prevent the production of the unwanted protein by blocking the translation of mRNA.
The DxTerity approach differs from normal antisense therapeutics because the initial materials are designed to be inactive requiring in-situ activation that is dependant on the expression of the target gene. If successful, the resulting new class of molecules could display exquisite specificity with reduced side effects.
“Our goal is to utilize the unique properties available with the NEAT™ technology to overcome some of the current limitations associated with antisense therapeutics,” said Arthur. D. Riggs, Ph.D., Chair, Department of Diabetes & Metabolic Diseases Research and Emeritus Director, Beckman Research Institute of the City of Hope.
According to Dr. Bob Terbrueggen, President and founder of DxTerity Diagnostics, “DxTerity is excited to be collaborating with City of Hope, whose recognized experience and expertise in developing drugs should accelerate the progress of this new class of antisense therapeutics. Our hope is that their well-developed model systems and scientific expertise will enable the rapid identification and evaluation of new drug candidates.”
Terms of the agreement have not been disclosed.
Schizophrenics' Blood Contains RNA From More MicrobesNews
The blood of schizophrenia patients features genetic material from more types of microorganisms than that of people without the debilitating mental illness, research at Oregon State University has found. What’s not known is whether that’s a cause or effect of the severe, chronic condition that strikes about one person in 100.READ MORE
Faulty Gene Leads to Alcohol-Induced Heart FailureNews
A faulty gene interacts with alcohol to accelerate heart failure in susceptible patients, a study suggests. This dangerous interaction can occur even when only moderate amounts of alcohol have been consumed.READ MORE
Bicycle Therapeutics Expands Strategic Partnership with AstraZenecaNews
New programs added in respiratory and cardio-metabolic diseases.READ MORE
Comments | 0 ADD COMMENT
2nd Annual Artificial Intelligence in Drug Development Congress
Sep 20 - Sep 21, 2018